Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer - Zhou, Qian; Liang, Jinxia; Yang, Tong; Liu, Jin; Li, Bo; Li, Yingchang; Fan, Zhenzhen; Wang, Weida; Chen, Wensheng; Yuan, Sujing; Xu, Meng; Xu, Qigui; et al. (EMBO molecular medicine, 2022)
Keywords: Animals; Antibodies; Antigen (tumor-associated); Bone marrow; Cancer therapies; Cellular Reprogramming; Cytokines; Drug dosages; EMBO03; EMBO19; Endoribonucleases; Experiments; FDA approval; Humans; Immune checkpoint; Immune Checkpoint Inhibitors - pharmacology; Immune system; immunotherapy; Inhibitor drugs; Kinases; Ligands; Lung cancer; Lung Neoplasms - drug therapy; Lymphocytes; Lymphocytes T; M1 macrophage; M2 macrophage; Macrophages; Mice; Mice, Transgenic; Multiple myeloma; Oligopeptides - pharmacology; Patients; Protein folding; Protein Serine-Threonine Kinases; Proteins; Solid tumors; Targeted cancer therapy; TRAF2 protein; Transgenic animals; Transgenic mice; Tumor cells; Tumor Microenvironment; Tumor necrosis factor-TNF; Tumor-Associated Macrophages - immunology; Tumors; tumor‐associated macrophage; tumor‐associated macrophage; M2 macrophage; tumor microenvironment; M1 macrophage; immunotherapy; tumor-associated macrophage